What diseases does dabrafenib treat? What are the indications?

Dabrafenib/Dabrafenib Trade name Tafinlar is a targeted drug, mainly used to treat some cancers related to specific gene mutations, especially malignant tumors related to BRAF mutation positivity. The BRAF gene is a gene encoding a kinase and is involved in cell proliferation and differentiation. When this gene is mutated, it can lead to uncontrolled cell proliferation, thereby promoting the occurrence and development of tumors. Dabrafenib effectively prevents the growth of cancer cells by inhibiting the abnormal activity caused by BRAF mutations. The indications of dabrafenib mainly include:

1. Advanced melanoma: Dabrafenib was first approved for the treatment of patients with advanced or metastatic melanoma with BRAF V600E or V600K mutations. Melanoma is a cancer that starts in the pigment cells of the skin. BRAF mutations are very common in melanoma, and these mutations can cause tumor cells to grow out of control. By inhibiting these mutated BRAF proteins, dabrafenib helps slow tumor growth and prolong patient survival.

2. Local advanced or metastatic non-small cell lung cancer (NSCLC): Dabrafenib is also used to treat patients with BRAF mutation-positive advanced non-small cell lung cancer. Non-small cell lung cancer is the most common type of lung cancer, and approximately 2-3% of patients have BRAF mutations. For these patients, dabrafenib can significantly delay tumor progression and improve patients' quality of life.

3. Thyroid cancer: Dabrafenib is also approved for the treatment of advanced or metastatic thyroid cancer with the BRAF V600E mutation, especially in patients who cannot be treated with surgery. BRAF mutations are common in thyroid cancer, and treatment with dabrafenib can effectively inhibit tumor growth.

In clinical applications, dabrafenib is usually used in combination with MEK inhibitors (such astrametinib). This combination therapy can not only effectively improve the therapeutic effect, but also reduce the occurrence of drug resistance. Combination therapy has been widely used in patients with BRAF mutation-positive melanoma and non-small cell lung cancer.

Reference materials:https://go.drugbank.com/drugs/DB08912